Skip to main content
. Author manuscript; available in PMC: 2019 Aug 13.
Published in final edited form as: Leukemia. 2019 Feb 13;33(8):1934–1943. doi: 10.1038/s41375-019-0402-3

Figure 2: Three groups of pediatric induction failure AML identified by whole-genome and RNA sequencing analysis.

Figure 2:

(a) Tile plot of recurrently mutated genes and gene expression profiles by patient, showing three disease groups, as labeled, with each row listing the mutant gene, and each column representing an individual patient specimen: Group 1, defined by NUP98 alterations (patients with NUP98-NSD1 fusions except patient 1 with NUP98 gain); Group 2, defined by WT1 mutations, and Group 3, defined by the apparent absence of NUP98 or WT1 mutations. (b) Gene set enrichment analysis (GSEA) of the three patient groups, listing significantly enriched (red) and downregulated (blue) gene sets, as a function of their normalized enrichment.